Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Liabilities and Shareholders Equity (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $8.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 43.68% year-over-year to $8.6 million, compared with a TTM value of $42.9 million through Sep 2025, down 37.28%, and an annual FY2024 reading of $13.5 million, down 31.4% over the prior year.
  • Liabilities and Shareholders Equity was $8.6 million for Q3 2025 at Arcadia Biosciences, up from $7.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $70.8 million in Q1 2021 and bottomed at $7.8 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $30.2 million, with a median of $26.8 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 119.55% in 2021, then crashed 55.16% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $43.9 million in 2021, then tumbled by 34.15% to $28.9 million in 2022, then tumbled by 31.87% to $19.7 million in 2023, then tumbled by 31.4% to $13.5 million in 2024, then tumbled by 36.49% to $8.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for RKDA at $8.6 million in Q3 2025, $7.8 million in Q2 2025, and $13.0 million in Q1 2025.